Ann: Extension to SPP Closing Date, page-44

First 44 Last

Share
Profile

Follow
Redchedder

200 Posts.

96

27/10/21

16:55

Post #: 57120237
Share

Originally posted by SaberX: ↑

Still think this was a bit of a dog's breakfast. Whichever way you look at it you can see why retail holders would be damned if they do, damned if they don't.

Without the quarterly retail holders are left suspecting something is amiss given first thoughts are this would be a no brainer to release prior to a raising, or even prior to the Kaddy acquisition - surely a rough idea of the quarterly numbers would have been known prior to announcing the deal which bodes the question of how much value could have potentially been missed for shareholders. Obviously talks wouldn't have happened overnight, so they've drawn the bow and pushed on ahead. If the quarterly is good - then you have to ask the question as a shareholder why all the dilution at a lower price - essentially giving Kaddy holders and founders more of a free lunch.

On the flip side the lack of a quarterly and the amount of dilution in succession means holders don't have any idea of how the Parton integration has started to play out - so jumping into the SPP is a leap of faith. Case of chicken or the egg first, but the share price at 5.5/5.6 clearly shows the indecision where one could merely buy on market and get exactly what they want or need, than lucky dip in the SPP. The extension now of the SPP to allow for the quarterly (speculating) to be digested also proves a catch 22 - if it blows it out of the water then suddenly all the applications result in a scale back, and you would have been better off buying on market anyway. If this occurs refer back to first point above where they've sold DW8 holders short by doing the Kaddy deal at a much lower share price with (one would assume) knowledge of a good quarterly dropping.

Still find it concerning with the amount of dilution - first Partons, and in succession all the milestones of performance shares (how much can be attributed to acquisitions for the sake of hitting rights vs strategically sound acquisitions that happened to serve dual purposes by coincidence?), and the lack of a quarter or two to digest how the strategy plays out. There are some LT holders here who back all the dilution for the long term faith in Dean - which is fine, but I'd imagine there's a fair bit of apprehension in the market on how it plays out.

it would be good to clarify or even have (if it isn't already) future performance rights tied to the core businesses financial metrics, thereby removing acquisition led growth to metrics resulting in performance rights being hit. This was clarified in the Kaddy presentation - which is good. Still think the Kaddy guys are laughing all the way to the bank though with the least to potentially lose from this.

Expand

If i'm the Kaddy founders watching DW8 SP death spiral over the last few months I'm waiting until the share price bottoms out before a deal goes ahead so I can get as many shares as possible.

Kaddy aquisition may have been on the Cards for months but why pull the trigger in the 15c's when you can feast on shares at 5.6c

Deal may have been enivitable months ago if the SP was more stable.

DW8 Price at posting: 5.7¢ Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

The iron ore comeback: Can it last?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HAS

Hastings progressing Yangibana to production with lower costs

There are more pages in this discussion • 25 more messages in this thread...

First 44 Last

Add KDY (ASX) to my watchlist

(20min delay)
Last 2.7¢		Change 0.000(0.00%)		Mkt cap ! $3.834M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Extension to SPP Closing Date, page-44

The iron ore comeback: Can it last?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Hastings progressing Yangibana to production with lower costs

Featured News

Featured News

Ann: Extension to SPP Closing Date, page-44

Top Stories

The iron ore comeback: Can it last?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Hastings progressing Yangibana to production with lower costs

Featured News

Featured News